Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Nurix Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 24.83 · gapped above the open, then crossed back over prior close. High/low 25.08 at 9:30 am ET, 24.30 at 1:15 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler & Co. (Piper Sandler), which was amended in July 2024 and again in October 2024 (as amended, the Second Amended Equity Distribution Agreement), pursuant to which, from time to time, we may offer and sell through Piper Sandler up to $300.0 million of the common stock registered under the shelf registration statement pursuant to one or more "at the market" offerings.”
FILING10-K0001549595-26-000016cik 0001549595
“For example, in March 2023, Silicon Valley Bank (SVB), which was one of our banking partners, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver, and in March 2023, Silvergate Capital Corp. and Signature Bank were similarly swept into receivership.”
FILING10-K0001549595-26-000016cik 0001549595
“Upon signing the Gilead Agreement, Gilead paid us an upfront payment of $45.0 million, plus $3.0 million in additional fees.”
FILING10-K0001549595-26-000016cik 0001549595
“Under the terms of the Pfizer Agreement, we received an upfront payment of $60.0 million.”
FILING10-K0001549595-26-000016cik 0001549595
“Upon signing the Sanofi Agreement, Sanofi paid us an upfront payment of $55.0 million.”
FILING10-K0001549595-26-000016cik 0001549595
“Although we may receive potential future milestone payments under our collaborations with Gilead, Sanofi and Pfizer, we do not currently have any committed external source of funds.”
FILING10-K0001549595-26-000016cik 0001549595
“In December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020 (as subsequently expanded and amended, the Sanofi Agreement), to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas using our DEL-AI platform to identify small molecules designed to induce degradation of three specified initial drug targets.”
FILING10-K0001549595-26-000016cik 0001549595
“In September 2023, we entered into a strategic collaboration with Seagen Inc. (now a part of Pfizer Inc.) (the Pfizer Agreement) to develop a suite of targeted protein degraders against multiple targets nominated by Pfizer that are suitable for antibody conjugation.”
FILING10-K0001549595-26-000016cik 0001549595
Watchlist prices, news filtered to it, and its next report on your desk.
Nurix Therapeutics, Inc. has 2 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Nurix Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NRIX (Nurix Therapeutics, Inc.) has 2 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PIPR +0.15%, in financials.